Consultants Forum Advertise
Subscribe
Close

  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Subscribe Now
Renew

Area Development - Site Selection, Facility Planning and Workforce Development

Biopharmaceutical Researchers-Manufacturers Anchor USD Discovery Campus in Sioux Falls, South Dakota

06/15/2018
SAB Biotherapeutics and Alumend will become USD Discovery District’s anchor tenants, at the 80-acre planned corporate and academic research park adjacent to the University Center in northwest Sioux Falls, South Dakota.

The campus will provide access to research facilities and infrastructure for research business development and foster collaboration for the commercialization of new technologies.

According to the Governor’s Office of Economic Development, the $30.9 million project will encompass not only a large multi-tenant research building, but also South Dakota’s first commercial cGMP (Current Good Manufacturing Practice) biotherapeutics manufacturing facility.

The first building will be an 84,000 square-foot multi-tenant research laboratory, office and biopharmaceutical manufacturing space. In addition to primary long-term tenants SAB Biotherapeutics and Alumend, the building will house the USD Discovery District offices and offer 20,000 square-feet of open leasable space.

The second building is a 42,000 square-foot commercial biomanufacturing production facility. SAB plans to use the building for its commercial biotherapeutics production operations. Funding for the facility was granted to the district by the GOED, and will also create an evergreen fund to seed future Discovery District projects.

The complex made possible by an historic strategic and financing partnership among the State of South Dakota, the University of South Dakota, the City of Sioux Falls, the Board of Regents and the business community through Forward Sioux Falls.

“The direct economic impact of the Discovery District, at full build out, is projected to include 26 privately developed buildings with facility construction value exceeding $314 million, employing almost 2,800 people through companies located in the District,” said Rich Naser, President of the USD Discovery District.

There are board and other approvals needed to finalize the financing and continue design work on the project. “There’s still work to be done,” added Naser. “Our goal is to break ground this fall and have the first building completed in 2020.

GOED said it has long supported the rapidly emerging biotech industry in South Dakota, and facilitated a significant financing package including state loans and grants, in addition to USD Foundation participation, to ensure a home not only for SAB Biotherapeutics and Alumend, but additional space for future biotech companies emerging in the state or choosing to relocate here, too.

“Both SAB Biotherapeutics and Alumend are bio-leaders in South Dakota,” said USD president James W. Abbott. “More importantly, they are on the cutting edge in their sectors, developing and commercializing breakthrough, life-saving solutions. They are innovators, exactly the kind of company we want to attract to the USD Discovery District.”

SAB Biotherapeutics is a clinical-stage biopharmaceutical company developing human antibody therapeutics using its first-of-its-kind immunotherapy platform leveraging transgenic cattle. The company will occupy approximately 41,000 square-feet of the first building with its corporate headquarters, research laboratories and cGMP biomanufacturing suite and plans to occupy the second building with its commercial manufacturing operations.

“The company chose to build our business in South Dakota because of the ability to get things done and move the business forward,” said Eddie J. Sullivan, SAB Biotherapeutics, Inc. President, CEO, and co-Founder. “We’ve now doubled in size since 2014, completed multiple successful clinical trials and our building our first production pharm near Canton. Clearly, it was a good decision.

The USD Discovery District is really the ideal place for us to continue to grow and spur additional bioscience development as well,” he added.

Alumend LLC, Avera’s wholly owned applied research and development company, will establish its corporate office and research laboratory in the district, occupying approximately 7,500 square feet. Alumend scientists have developed Natural Vascular Scaffolding (NVS) therapy, a novel drug/device combination for the treatment of peripheral vascular disease (PVD). They will continue their research and development of other uses of the NVS chemistry with potential applications in cancer, orthopedics, cosmetics at the Discovery District.

“Through our work with Alumend, Avera has been a proud participant in South Dakota’s biotech industry for the past two decades, and we’re thrilled to be an anchor company in the Discovery District,” said Ryan Hansen, Executive Director, Avera Research Institute.

The USD Discovery District continues to work with the City of Sioux Falls on long-term infrastructure development for the Discovery District, but more immediately on the streets, utilities, streetscape and parking needed to utilize the 3.7-acre site for SAB Biotherapeutics and Alumend.

Exclusive Research